ES2069836T3 - Sulfato de 3-(2-(dimetilamino)etil)-n-metil-1h-indol-5-metanosulfonamida(2:1). - Google Patents

Sulfato de 3-(2-(dimetilamino)etil)-n-metil-1h-indol-5-metanosulfonamida(2:1).

Info

Publication number
ES2069836T3
ES2069836T3 ES91311583T ES91311583T ES2069836T3 ES 2069836 T3 ES2069836 T3 ES 2069836T3 ES 91311583 T ES91311583 T ES 91311583T ES 91311583 T ES91311583 T ES 91311583T ES 2069836 T3 ES2069836 T3 ES 2069836T3
Authority
ES
Spain
Prior art keywords
indol
dimethylamine
ethyl
methyl
methanosulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91311583T
Other languages
English (en)
Spanish (es)
Inventor
Joanne Craig
Derek Leslie Crookes
Stephen John Skittrall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2069836T3 publication Critical patent/ES2069836T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
ES91311583T 1990-12-12 1991-12-12 Sulfato de 3-(2-(dimetilamino)etil)-n-metil-1h-indol-5-metanosulfonamida(2:1). Expired - Lifetime ES2069836T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909026998A GB9026998D0 (en) 1990-12-12 1990-12-12 Medicaments

Publications (1)

Publication Number Publication Date
ES2069836T3 true ES2069836T3 (es) 1995-05-16

Family

ID=10686904

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91311583T Expired - Lifetime ES2069836T3 (es) 1990-12-12 1991-12-12 Sulfato de 3-(2-(dimetilamino)etil)-n-metil-1h-indol-5-metanosulfonamida(2:1).

Country Status (36)

Country Link
US (2) US5554639A (https=)
EP (1) EP0490689B1 (https=)
JP (1) JP2994037B2 (https=)
KR (1) KR100211479B1 (https=)
CN (2) CN1030890C (https=)
AP (1) AP230A (https=)
AT (1) ATE119881T1 (https=)
AU (1) AU650706B2 (https=)
BE (1) BE1005085A3 (https=)
CA (1) CA2098302C (https=)
CH (1) CH684192A5 (https=)
CY (1) CY2005A (https=)
CZ (1) CZ281931B6 (https=)
DE (1) DE69108200T2 (https=)
DK (1) DK0490689T3 (https=)
EG (1) EG20219A (https=)
ES (1) ES2069836T3 (https=)
FR (1) FR2670487B1 (https=)
GB (2) GB9026998D0 (https=)
GR (1) GR3015430T3 (https=)
HK (1) HK82697A (https=)
HU (1) HU211937A9 (https=)
IE (1) IE62894B1 (https=)
IL (1) IL100330A (https=)
IS (1) IS1706B (https=)
IT (1) IT1252868B (https=)
MX (1) MX9102501A (https=)
MY (1) MY109265A (https=)
NL (1) NL9102071A (https=)
NZ (1) NZ240942A (https=)
PT (1) PT99757B (https=)
RU (1) RU2108328C1 (https=)
TW (2) TW300886B (https=)
WO (1) WO1992010477A1 (https=)
YU (1) YU48926B (https=)
ZA (1) ZA919750B (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO114326B1 (ro) * 1992-06-05 1999-03-30 Merck Sharp & Dohme Limited Ho Sarea sulfat a unui triazol substituit, procedeu de obtinere a acesteia, compozitie farmaceutica si procedeu de obtinere a acesteia
FR2749846B1 (fr) * 1996-06-17 1998-09-11 Pf Medicament Sel de methanesulfonate d'une arylpiperazine derivee de tryptamine et ses solvates pour usage pharmaceutique
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6106837A (en) * 1997-05-15 2000-08-22 Hirsch; Alan R. Method of treating headaches, and article of manufacture therefor
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US6426084B1 (en) * 2000-06-19 2002-07-30 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6187790B1 (en) 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6132757A (en) * 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
GB9926250D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Chemical process
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US6458804B1 (en) 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US6562838B2 (en) * 2001-01-26 2003-05-13 R. T. Alamo Ventures I, L.L.C. Treatment of cardiovascular disease with quinolinone enantiomers
US6451813B1 (en) 2001-01-26 2002-09-17 R. T. Alamo Ventures I, Llc Treatment of gastroparesis in certain patient groups
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
DK1435945T3 (da) * 2001-06-05 2008-12-01 Ronald Aung-Din Topisk migræne terapi
US7041677B2 (en) * 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
US7208628B2 (en) * 2002-05-13 2007-04-24 Kansas State University Research Foundation Compositions and methods for the treatment of hepatitis C virus infection
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
WO2004060355A1 (en) * 2002-12-26 2004-07-22 Pozen Inc. Multilayer Dosage Forms Containing NSAIDs and Triptans
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (en) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Sumatriptan crystalline forms, pharmaceutical compositions and methods
US20070065463A1 (en) * 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
US20050089558A1 (en) * 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
WO2005119607A2 (en) * 2004-06-03 2005-12-15 Tyfone, Inc. System and method for securing financial transactions
WO2005123043A2 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
JP2008545650A (ja) 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
EP2026790A2 (en) 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders
EP2124556B1 (en) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
JP2010507585A (ja) * 2006-10-19 2010-03-11 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換インドール
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
GB2448183A (en) * 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
ES2620672T3 (es) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
CA2725618C (en) 2008-05-27 2016-04-12 Biota Scientific Management Pty Ltd Antiviral salts
CA2765866C (en) * 2008-06-20 2016-06-21 Alphapharm Pty Ltd Single phase pharmaceutical composition of a 5-ht1 inhibitor and an nsaid
US8809385B2 (en) 2008-06-23 2014-08-19 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8592424B2 (en) * 2008-06-30 2013-11-26 Afgin Pharma Llc Topical regional neuro-affective therapy
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
CA2775404C (en) 2009-09-25 2017-01-03 Dr. Reddy's Laboratories Limited Formulations comprising triptan compounds
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
HK1244715A1 (zh) 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
US10494405B2 (en) 2015-05-15 2019-12-03 The Regents Of The University Of Michigan Methods and compositions for the treatment of arthritis
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
AU2018366022B2 (en) 2017-11-07 2024-05-16 The Regents Of The University Of Michigan Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use
WO2020049523A1 (en) 2018-09-07 2020-03-12 Upsher-Smith Laboratories, Llc Methods of treating migraine
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
JP2023515535A (ja) * 2020-02-27 2023-04-13 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド リメゲパントの経口急速分散剤形

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB8615599D0 (en) * 1986-06-26 1986-07-30 Glaxo Group Ltd Chemical compounds
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
KR100211479B1 (ko) 1999-08-02
EP0490689A1 (en) 1992-06-17
AU650706B2 (en) 1994-06-30
CY2005A (en) 1997-12-05
TW205035B (https=) 1993-05-01
IS1706B (is) 1998-12-10
MX9102501A (es) 1992-09-01
ZA919750B (en) 1992-10-28
IE914317A1 (en) 1992-06-17
NL9102071A (nl) 1992-07-01
GR3015430T3 (en) 1995-06-30
TW300886B (https=) 1997-03-21
ITRM910922A1 (it) 1993-06-11
DK0490689T3 (da) 1995-05-22
BE1005085A3 (fr) 1993-04-13
AU9072091A (en) 1992-07-08
HK82697A (en) 1997-06-27
IE62894B1 (en) 1995-03-08
YU191491A (sh) 1994-04-05
GB2251614A (en) 1992-07-15
PT99757B (pt) 1999-05-31
AP9100339A0 (en) 1992-01-31
ATE119881T1 (de) 1995-04-15
IL100330A (en) 1996-06-18
PT99757A (pt) 1992-12-31
AP230A (en) 1993-01-27
EP0490689B1 (en) 1995-03-15
CA2098302A1 (en) 1992-06-13
IS3790A7 (is) 1992-06-13
GB9026998D0 (en) 1991-01-30
US5705520A (en) 1998-01-06
CA2098302C (en) 2001-10-16
FR2670487A1 (fr) 1992-06-19
CZ114093A3 (en) 1994-02-16
IL100330A0 (en) 1992-09-06
YU48926B (sh) 2002-12-10
JP2994037B2 (ja) 1999-12-27
CN1128259A (zh) 1996-08-07
EG20219A (en) 1997-11-30
CN1050831C (zh) 2000-03-29
JPH06503560A (ja) 1994-04-21
CZ281931B6 (cs) 1997-04-16
US5554639A (en) 1996-09-10
GB2251614B (en) 1994-12-14
DE69108200D1 (de) 1995-04-20
CN1063099A (zh) 1992-07-29
NZ240942A (en) 1994-03-25
CH684192A5 (fr) 1994-07-29
ITRM910922A0 (it) 1991-12-11
HU211937A9 (en) 1996-01-29
RU2108328C1 (ru) 1998-04-10
WO1992010477A1 (en) 1992-06-25
MY109265A (en) 1996-12-31
CN1030890C (zh) 1996-02-07
DE69108200T2 (de) 1995-07-20
GB9126297D0 (en) 1992-02-12
FR2670487B1 (fr) 1993-08-20
IT1252868B (it) 1995-06-28

Similar Documents

Publication Publication Date Title
ES2069836T3 (es) Sulfato de 3-(2-(dimetilamino)etil)-n-metil-1h-indol-5-metanosulfonamida(2:1).
AU549927B2 (en) 2-oxindole-1-carboxamide derivatives
RU93053493A (ru) Сульфатная соль (2:1)-3-[2-(диметиламино)этил]-n-метил-1н-индол-5-метансульфонамида и ее фармацевтически приемлемые сольваты, способ их получения, фармацевтические композиции на их основе, их применение в терапии, способ лечения головной боли
ES2145922T3 (es) Compuestos espiro-azabiciclicos utiles en terapia.
ES2117015T3 (es) Composiciones que contienen sumatriptan.
NO963053L (no) Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav
NO932670L (no) Blandinger
PH17786A (en) New methyl substituted 4-methoxy-pyridine-n-oxides to be used as intermediate in the preparation of the new intermediate
RU94035686A (ru) 4-ариламино-бензопиран и родственные соединения, фармацевтическая композиция, способ лечения
TW336939B (en) Lipopeptide derivatives, a process for their preparation and their use
NO892870D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
ES2091907T3 (es) Analogos octapeptidos de somatostina con una threonina en la sexta posicion.
DK0598770T3 (da) Pyrazinderivater samt fremstilling og anvendelse deraf
GT199700037A (es) Composiciones farmaceuticas para el tratamiento de la rinitis
ATE228364T1 (de) Indolalkaloide als antientzündliche wirkstoffe
LTIP1518A (en) Novel tetrazole derivatives, process for the preparing thereof and pharmaceutical composition comprising the same
AU1876792A (en) Pharmacologically enhanced formulations
DE3767114D1 (de) Stabilisierte arzneimittel.
YU31592A (sh) 6-HETEROCIKLIČNI-4-AMINO-1,2,2a,3,4,5- HEKSAHIDROBENZ (cd) INDOLI
AR011697A1 (es) Composiciones farmaceuticas, uso de lamivudina en la manufactura de tales composiciones farmaceuticas.
NZ246598A (en) Trazodone derivatives; compounds and preparation, pharmaceutical compositions; intermediate compounds
AU2774292A (en) Toiletries composition
SK60595A3 (en) Pharmaceutical agents containing gemfibrozil
ES2181407T3 (es) Glucocorticoides para tratar la glomerulonefritis.
ECSP941088A (es) Composiciones

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 490689

Country of ref document: ES